Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nanobiotix S.A. Sponsored ADR (NBTX : NSDQ)
 
 • Company Description   
Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company's proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France.

Number of Employees: 108

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.23 Daily Weekly Monthly
20 Day Moving Average: 3,888 shares
Shares Outstanding: 47.13 (millions)
Market Capitalization: $246.51 (millions)
Beta: 0.41
52 Week High: $6.00
52 Week Low: $2.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.20% -12.60%
12 Week 58.97% 33.71%
Year To Date 82.23% 70.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 RUE DE WATTIGNIES
-
PARIS,I0 75012
FRA
ph: 33-1-40-26-04-70
fax: -
None http://www.nanobiotix.com
 
 • General Corporate Information   
Officers
Dr. Laurent Levy - Chairman of the Executive Board and Co-founder
Dr. Gary Phillips - Chairman
Ms. Anne-Marie Graffin - Vice Chairwoman
Mr. Bart Van Rhijn - Chief Financial and Business Officer
Ms. Anne-Juliette Hermant - Chief People Officer

Peer Information
Nanobiotix S.A. Sponsored ADR (GSAC)
Nanobiotix S.A. Sponsored ADR (CASI)
Nanobiotix S.A. Sponsored ADR (ALCD.)
Nanobiotix S.A. Sponsored ADR (OMNN)
Nanobiotix S.A. Sponsored ADR (CGPI.)
Nanobiotix S.A. Sponsored ADR (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 63009J107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 47.13
Most Recent Split Date: (:1)
Beta: 0.41
Market Capitalization: $246.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.04
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.04
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -1.51
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©